Insider · CIK 0001855616
Martha Morrell
Files at NPCE (NeuroPace Inc). First filing Dec 7, 2023, latest Mar 4, 2026.
In brief
Martha Morrell files SEC Form 4 as officer at NPCE (NeuroPace Inc). Since Dec 7, 2023, Martha Morrell has reported 0 open-market buys worth $0 and 4 open-market sells worth $652k, the latest filed on Mar 4, 2026.
A track record needs three past buys with six months of prices behind them; Martha Morrell has 0, so none is measured yet.
The newest scored trade: sold $399k of NPCE on Dec 15, 2025, filed Mar 4, 2026, scored 21 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $399k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NPCE: NeuroPace Inc
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | NeuroPace Inc | $399k 25,000 shares | -33% | +93% from low-12% from high | |
| 11Weak | NeuroPace Inc | $136k 13,402 shares | -11% | +667% from low0% from high | |
| 0Weak | NeuroPace Inc | $28k 2,730 shares | -2% | +619% from low-6% from high | |
| 12Weak | NeuroPace Inc | $90k 11,005 shares | -8% | +537% from low-16% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 15, 2025 | NPCE NEUROPACE, INC. | 25,000 0.08% of outstanding | $405k | Dec 15, 2025 | none |
| Jan 30, 2025 | NPCE NEUROPACE INC | 78,534 0.26% of outstanding | $1.2M | Jan 30, 2025 | $50k |
| Jan 29, 2025 | NPCE NEUROPACE INC | 100 0.00% of outstanding | $1,413 | Jan 29, 2025 | $48k |
| Jan 24, 2025 | NPCE NEUROPACE INC | 3,200 0.01% of outstanding | $45k | Jan 24, 2025 | none |
| Dec 20, 2023 | NPCE NeuroPace Inc. | 48,397 0.18% of outstanding | $483k | Dec 20, 2023 | $90k |
| Dec 6, 2023 | NPCE NeuroPace Inc. | 11,005 0.04% of outstanding | $90k | Dec 6, 2023 | none |
Transactions
Every row this insider has filed, 25 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | NPCE NeuroPace Inc | FTax withholding Common Stock | -335 | $13.97 | $4,680 | 51,357 | 19 d ago |
| Aug 27, 2026 | NPCE NeuroPace Inc | FTax withholding Common Stock | -358 | $14.13 | $5,059 | 51,692 | Aug 28, 2026 |
| Jun 24, 2026 | NPCE NeuroPace Inc | FTax withholding Common Stock | -335 | $16.22 | $5,434 | 52,050 | Jun 25, 2026 |
| May 27, 2026 | NPCE NeuroPace Inc | FTax withholding Common Stock | -358 | $17.06 | $6,107 | 52,385 | May 28, 2026 |
| May 15, 2026 | NPCE NeuroPace Inc | AGrant or award Common Stock | +5,460 | $0.00 | $0 | 52,743 | May 19, 2026 |
| May 15, 2026 | NPCE NeuroPace Inc | AGrant or award Stock Option (Right to Buy)derivative | +14,550 | $0.00 | $0 | 14,550 | May 19, 2026 |
| Mar 24, 2026 | NPCE NeuroPace Inc | FTax withholding Common Stock | -1,341 | $13.27 | $18k | 47,283 | Mar 25, 2026 |
| Dec 15, 2025 | NPCE NeuroPace Inc | SOpen-market sale Common Stock10b5-1 | -25,000 | $15.97 | $399k | 49,964 | Mar 4, 2026 |
| Mar 3, 2026 | NPCE NeuroPace Inc | FTax withholding Common Stock | -1,340 | $13.83 | $19k | 48,624 | Mar 4, 2026 |
| Feb 27, 2026 | NPCE NeuroPace Inc | FTax withholding Common Stock | -358 | $14.58 | $5,220 | 74,964 | Mar 2, 2026 |
| Feb 20, 2026 | NPCE NeuroPace Inc | FTax withholding Common Stock | -3,412 | $14.34 | $49k | 75,322 | Feb 23, 2026 |
| Dec 3, 2025 | NPCE NeuroPace Inc | FTax withholding Common Stock | -1,338 | $16.66 | $22k | 78,734 | Dec 4, 2025 |
| Nov 27, 2025 | NPCE NeuroPace Inc | FTax withholding Common Stock | -357 | $16.50 | $5,891 | 80,072 | Dec 1, 2025 |
| Nov 20, 2025 | NPCE NeuroPace Inc | FTax withholding Common Stock | -3,051 | $13.50 | $41k | 80,429 | Nov 24, 2025 |
| Sep 3, 2025 | NPCE NeuroPace Inc | FTax withholding Common Stock | -1,337 | $9.36 | $13k | 83,480 | Sep 4, 2025 |
| Aug 27, 2025 | NPCE NeuroPace Inc | FTax withholding Common Stock | -357 | $8.88 | $3,170 | 84,817 | Aug 28, 2025 |
| Aug 20, 2025 | NPCE NeuroPace Inc | FTax withholding Common Stock | -3,052 | $8.66 | $26k | 85,174 | Aug 22, 2025 |
| Jun 3, 2025 | NPCE NeuroPace Inc | FTax withholding Common Stock | -1,338 | $13.54 | $18k | 85,943 | Jun 6, 2025 |
| May 27, 2025 | NPCE NeuroPace Inc | FTax withholding Common Stock | -357 | $12.66 | $4,520 | 87,281 | May 29, 2025 |
| May 20, 2025 | NPCE NeuroPace Inc | FTax withholding Common Stock | -3,051 | $17.99 | $55k | 87,638 | May 21, 2025 |
| Apr 22, 2025 | NPCE NeuroPace Inc | FTax withholding Common Stock | -237 | $10.94 | $2,593 | 90,689 | Apr 23, 2025 |
| Dec 26, 2023 | NPCE NeuroPace Inc | SOpen-market sale Common Stock10b5-1 | -102 | $10.00 | $1,020 | 123,327 | Dec 28, 2023 |
| Dec 27, 2023 | NPCE NeuroPace Inc | SOpen-market sale Common Stock10b5-1 | -13,300 | $10.12 | $135k | 110,027 | Dec 28, 2023 |
| Dec 20, 2023 | NPCE NeuroPace Inc | SOpen-market sale Common Stock10b5-1 | -2,730 | $10.14 | $28k | 123,429 | Dec 22, 2023 |
| Dec 6, 2023 | NPCE NeuroPace Inc | SOpen-market sale Common Stock10b5-1 | -11,005 | $8.16 | $90k | 126,159 | Dec 7, 2023 |
Questions about Martha Morrell
Answered from the filings on this page, as of the latest one.
Is Martha Morrell buying or selling?
In the last 12 months Martha Morrell reported 0 open-market buys worth $0 and 1 open-market sell worth $399k on SEC Form 4; the latest was sold $399k of NPCE on Dec 15, 2025. Grants, option exercises and tax withholding are not counted.
How did Martha Morrell's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Martha Morrell has 0.
Where does Martha Morrell file Form 4?
Martha Morrell has filed Form 4 at NPCE (NeuroPace Inc) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.